PharmTech Weekly Roundup-March 27, 2026

In news this week, Merck’s multi-billion-dollar acquisition of Terns Pharmaceuticals reinforces the industry’s focus on allosteric inhibition as a primary strategy to overcome drug resistance in oncology.The deal centers on TERN-701, an investigational oral drug candidate.

The FDA approved the first therapy for Hunter syndrome's neurologic symptoms via surrogate endpoint, signaling evolving rare disease development standards, demonstrating a growing regulatory flexibility toward using biochemical surrogate endpoints to fast-track treatments for ultra-rare diseases.

In conference news, PDA Week saw discussions on a variety of topics. Malav Parikh, director, Quality Risk Management, Global Quality Compliance and Systems, Takeda moderated a session on the adoption of digital simulations for transport validation and 2D barcodes with digital footprints to combat increasingly sophisticated global counterfeiting. Ryan Murray of ValSource spoke about the use of a holistic contamination control strategy, supported by innovative far-UVC technology and robust environmental monitoring, for maintaining a consistent state of compliant control was also featured. Richard Jaenisch and David Jaenisch highlighted how digitally interactive SOPs are enabling adaptive, competency-focused workforce training that ensures no learner falls behind during intensive technical workshops; and a Human-AI Training Parallelization framework provides a transparent method for integrating generative AI into existing workflows while strictly protecting sensitive intellectual property. Check out PharmTech.com to watch interviews with some of the PDA Week session speakers.

At DCAT Week 2026, manufacturers announced commitments to expanding domestic finished-dose capacity and specialized technologies like high-potency spray drying to mitigate global supply chain risks. CDMOs like Olon are building end-to-end manufacturing chains for antibody-drug conjugates while pioneering sustainable, methanol-free fermentation processes at an industrial scale.

New content on PharmTech.com this week included a look at advancements in ensuring drug product quality. Quality was a key topic this week with the latest episode of Ask the Expert discussing how preventing high-level recalls requires a proactive quality unit that regularly walks the shop floor to identify systemic vulnerabilities and human errors before they reach the patient. Columnist Cheryl Barton also took a look at how Europe is implementing its most significant pharmaceutical legislation in two decades, introducing joint clinical assessments to harmonize evaluations and expedite patient access.

USP’s Tony Lakavage provided his thoughts on industry trends and gave insight on how the US Pharmacopeia is utilizing its Medicine Supply Map to identify geographic concentration risks and advocate for the adoption of advanced manufacturing technologies.

Partha Anbil, a cognitive enterprise transformation leader with IBM’s Healthcare and Life Sciences practice, detailed how hybrid cloud architectures have become essential for balancing the massive computational power of the public cloud with the private infrastructure required for GxP compliance and IP security.

And Denis Beckford Vera, head of Radiopharmacology, Champion Oncology, explained how advancing radiopharmaceuticals requires bridging the preclinical-clinical gap by utilizing patient-derived xenograft models to provide more accurate clinical predictions.

Whether through the integration of Pharma 5.0 automation or the onshoring of critical ingredients, the goal remains the same: ensuring a resilient supply of high-quality medicines. Staying informed on these integrated strategies is no longer optional—it is a requirement for modern pharmaceutical leadership.

Be sure to visit PharmTech.com to watch this week’s interviews and read the latest news and technical articles.